Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ICON and Proteome Sciences have entered into a strategic alliance to provide pharmaceutical companies with an expanded biomarker solution to allow earlier assessments in the development of new medicines.
Subscribe to our email newsletter
ICON said that with this alliance it is strengthening its current biomarker solution to include an integrated suite of labeling, separation and mass spectrometry technologies for protein and peptide profiling in complex biological materials.
ICON Development Solutions Biomarker Lab Services John Allinson said that they are extremely pleased to be entering this long-term partnership with Proteome Sciences which allows them to offer the clients access to state of the art protein and peptide profiling and rapid development of mass spectrometry assays through PS Biomarker Services.
Proteome chief operating officer Ian Pike said that they are delighted to be partnering with the team at ICON Development Solutions to provide their clients with a complete biomarker solution, including PS Biomarker Discovery Services as part of wider clinical development programs.
"The power of our proprietary technology platforms to identify and validate key protein biomarkers of disease and response to treatment is clearly being recognised and used by the pharmaceutical industry," Pike said.